Placental Growth Factor (PLGF) in the first trimester of pregnancy

Bibliography Edition: November 2013 Placental Growth Factor (PLGF) in the first trimester of pregnancy –Pre-eclampsia, SGA and trisomies Contents P...
Author: Clarence Stokes
0 downloads 1 Views 283KB Size
Bibliography Edition: November 2013

Placental Growth Factor (PLGF) in the first trimester of pregnancy –Pre-eclampsia, SGA and trisomies

Contents Pre-eclampsia and SGA Combined Screening for Preeclampsia and Small for Gestational Age at 11–13 Weeks*..........8 Poon L.C.Y., Syngelaki A., Akolekar R., Lai J., Nicolaides K.H. Vol. 33, No. 1, 2013 Issue release date: January 2013 Fetal Diagn Ther 2013;33:16–27

Maternal Characteristics, Mean Arterial Pressure and Serum Markers in Early Prediction of Preeclampsia*..............................................................................................................................9 Sylwia Kuc, Maria P. H. Koster, Arie Franx, Peter C. J. I. Schielen, Gerard H. A. Visser PLOS ONE, 2013; 8(5): e63546

Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy..........................10 M. PARRA-CORDERO, R. RODRIGO†, P. BARJA, C. BOSCO†, G. RENCORET, A. SEPÚ LVEDA-MARTINEZ and S. QUEZADA Ultrasound Obstet Gynecol 2013; 41: 538–544

Competing Risks Model in Early Screening for Preeclampsia by Biophysical and Biochemical Markers*........................................................................................11 R Akolekar, A Syngelaki, L Poon, D Wright, K. H. Nicolaides Fetal Diagn Ther. 2013, 33:8-15

Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population? ...........12 L Myatt, RG Clifton, JM Roberts, CY Spong, RJ Wapner, JM Thorp Jr, BM Mercer, AM Peaceman, SM Ramin, MW Carpenter, A Sciscione, JE Tolosa, G Saade, Y Sorokin, GD Anderson, for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network DOI: 10.1111/1471-0528.12128. www.bjog.org. Accepted 20 November 2012. Published Online 18 January 2013.

Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: type 1 versus type 2 preeclampsia?..............................................13 Powers RW, Roberts JM, Plymire DA, Pucci D, Datwyler SA, Laird DM, Sogin DC, Jeyabalan A, Hubel CA, Gandley RE. Hypertension. 2012 Jul; 60(1):239-46.

A Comparison of Two Immunoassay Methods for the Measurement of Maternal Serum Placental Growth Factor in Early Pregnancy*.............................................14 N.J. Cowans, M. Kisanga, A. Khan, K. Spencer Fetal Diagn Ther 2012;31:254-259

First trimester maternal serum PIGF, free ß-hCG, PAPP-A, PP-13, uterine artery Doppler and maternal history for the prediction of preeclampsia*..........................................15 Di Lorenzo G, Ceccarello M, Cecotti V, Ronfani L, Monasta L, Vecchi Brumatti L, Montico M, D’Ottavio G. Placenta 2012, 1-7

Uterine artery Doppler and biochemical markers (PAPP-A, PIGF, sFlt-1, P-selectin, NGAL) at 11 + 0 to 13 + 6 weeks in the prediction of late (> 34 weeks) pre-eclampsia. ...........................16 Youssef A, Righetti F, Morano D, Rizzo N, Farina A. Prenat Diagn 2011 Dec;31(12):1141-6. doi: 10.1002/pd.2848. Epub 2011 Oct 28

2

*DELFIA Chemistry used in PlGF assay

Contents Stability of first trimester placental growth factor in serum and whole blood*.....................17 N. J. Cowans, H. Alfthan, U. H. Stenman and K. Spencer Prenat Diagn. 2011 Dec;31(12):1193-7. doi: 10.1002/pd.2894. Epub 2011 Oct 26.

First trimester screening for intra-uterine growth restriction and early-onset pre-eclampsia*...............................................................................................................................18 G. Vandenberghe, I. Mensink, J. W. R. Twisk, M. A. Blankenstein, A. C. Heijboer and J. M. G. van Vugt Prenat Diagn 2011; 31: 955–961.

Longitudinal trends in fetoplacental biochemical markers, uterine artery pulsatility index and maternal blood pressure during the first trimester of pregnancy*....................................19 E. J. Wortelboer, M. P. H. Koster, S. Kuc, M. J. C. Eijkemans, C. M. Bilardo, P. C. J. I. Schielen and G. H. A. Visser Ultrasound Obstet Gynecol 2011; 38: 383–388

Screening for pre-eclampsia–lessons from aneuploidy screening.............................................20 Cuckle HS. Placenta. 2011 Feb;32 Suppl:S42-8

Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks................................................................21 Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prenat Diagn 2011 Jan;31(1):66-74.

Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women*...........................................................................22 Audibert F, Boucoiran I, An N, Aleksandrov N, Delvin E, Bujold E, Rey E. Am J Obstet Gynecol. 2010 Oct;203(4):383.e1-8.

First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset pre-eclampsia*..............................23 Wortelboer EJ, Koster MP, Cuckle HS, Stoutenbeek PH, Schielen PC, Visser GH. BJOG. 2010 Oct;117(11):1384-9.

First-trimester placental growth factor as a marker for hypertensive disorders and SGA*....24 Cowans NJ, Stamatopoulou A, Matwejew E, von Kaisenberg CS, Spencer K. Prenat Diagn 2010 Jun;30(6):565-70.

Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks............................................................................................25 Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH. Ultrasound Obstet Gynecol. 2010 Jun;35(6):662-70.

Placental growth factor in the first trimester: relationship with maternal factors and placental Doppler studies......................................................................................................26 Kasdaglis T, Aberdeen G, Turan O, Kopelman J, Atlas R, Jenkins C, Blitzer M, Harman C, Baschat AA. Ultrasound Obstet Gynecol. 2010 Mar;35(3):280-5.

*DELFIA Chemistry used in PlGF assay

3

Contents First-trimester prediction of hypertensive disorders in pregnancy............................................27 Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. Hypertension. 2009 May;53(5):812-8. Epub 2009 Mar 9.

First trimester urinary placental growth factor and development of pre-eclampsia...............28 Savvidou MD, Akolekar R, Zaragoza E, Poon LC, Nicolaides KH. BJOG. 2009 Apr;116(5):643-7. Epub 2009 Feb 10.

Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation........................................................................................29 Poon LC, Zaragoza E, Akolekar R, Anagnostopoulos E, Nicolaides KH. Prenat Diagn. 2008 Dec;28(12):1110-5.

Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia..........................................................................30 Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH. Ultrasound Obstet Gynecol. 2008 Nov;32(6):732-9.

Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia?.................................................................................................................................31 Sibai BM, Koch MA, Freire S, Pinto e Silva JL, Rudge MV, Martins-Costa S, Bartz J, de Barros Santos C, Cecatti JG, Costa R, Ramos JG, Spinnato JA 2nd. Am J Obstet Gynecol. 2008 Sep;199(3):268.e1-9.

The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age.............................................. 32-33 Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, Gotsch F, Edwin S, Nien JK, Chaiworapongsa T, Mittal P, Mazaki-Tovi S, Than NG, Gomez R, Hassan SS. J Matern Fetal Neonatal Med. 2008 May;21(5):279-87.

A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate................................................................................................... 34-35 Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, Chaiworapongsa T, Levine RJ, Karumanchi SA. J Matern Fetal Neonatal Med. 2008 Jan;21(1):9-23.

Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth..............................36 Smith GC, Crossley JA, Aitken DA, Jenkins N, Lyall F, Cameron AD, Connor JM, Dobbie R. Obstet Gynecol. 2007 Jun;109(6):1316-24.

Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia............................................................................................................37 Vatten LJ, Eskild A, Nilsen TI, Jeansson S, Jenum PA, Staff AC. Am J Obstet Gynecol. 2007 Mar;196(3):239.e1-6.

4

Contents Correlations of placental perfusion and PlGF protein expression in early human pregnancy............................................................................................................38 Welch PC, Amankwah KS, Miller P, McAsey ME, Torry DS. Am J Obstet Gynecol. 2006 Jun;194(6):1625-9; discussion 1629-31. Epub 2006 Apr 25.

Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia.....................................................................................................39 Thadhani R, Ecker JL, Mutter WP, Wolf M, Smirnakis KV, Sukhatme VP, Levine RJ, Karumanchi SA. Hypertension. 2004 May;43(5):988-92. Epub 2004 Mar 15.

Circulating angiogenic factors and the risk of preeclampsia.....................................................40 Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. N Engl J Med. 2004 Feb 12;350(7):672-83. Epub 2004 Feb 5

First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia..............................................................................................................41 Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, Ecker J, Karumanchi SA. J Clin Endocrinol Metab. 2004 Feb;89(2):770-5.

First-trimester maternal serum levels of placenta growth factor as predictor of preeclampsia and fetal growth restriction..............................................................................42 Ong CY, Liao AW, Cacho AM, Spencer K, Nicolaides KH. Obstet Gynecol. 2001 Oct;98(4):608-11. Comment in: Obstet Gynecol. 2001 Oct;98(4):596-9.

Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia.................................................................................................................43 Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS. Am J Obstet Gynecol. 2001 May;184(6):1267-72.

Trisomies Improvements in antenatal screening for Down’s syndrome*..................................................44 NJ Wald, JP Bestwickand, WJ Huttly J Med Screen 2013:1–21, DOI: 10.1177/0969141313476496

Maternal serum placental growth factor and a-fetoprotein testing in first trimester screening for Down syndrome*.......................................................................45 Kim Donalson, Steve Turner, Lesley Morrison, Päivi Liitti, Christel Nilsson and Howard Cuckle Prenatal Diagnosis 2013, 33, 457–461, DOI: 10.1002/pd.4087

First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing*...................................................................................................................46 K. H. NICOLAIDES, D. WRIGHT, L. C. POON, A. SYNGELAKI and M. GIL Ultrasound Obstet Gynecol 2013 Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.12511

*DELFIA Chemistry used in PlGF assay

5

Contents Antenatal Screening for Down Syndrome Using Serum Placental Growth Factor with the Combined, Quadruple, Serum Integrated and Integrated Tests*........................................47 Nicholas J. Wald, Jonathan P. Bestwick, Lynne M. George, Wayne J. Huttly PLoS ONE 7 (10): e46955

First trimester combined screening for trisomy 21 with different combinations of placental growth factor, free ß-hCG and PAPP-A*.......................................................................................48 KO Kagan, M Hoopmann, H Abele, R Alkier, K Lüthgens Ultrasound in Obstetrics & Gynecology 2012

Maternal Serum Placental Growth Factor in Prospective Screening for Aneuploidies at 8–13 Weeks’ Gestation.......................................................................................49 Pranav Pandya, David Wright, Argyro Syngelaki, Ranjit Akolekar, Kypros H. Nicolaides Fetal Diagn Ther, Published online: January 27, 2012, DOI: 10.1159/000335684 Fetal Diagn Ther, Published online: January 27, 2012

Modeling Down syndrome screening performance using first-trimester serum markers* .............................................................................................................................50 M. P. H. Koster, E. J. Wortelboer, P. Stoutenbeek, G. H. A. Visser and P. C. J. I. Schielen Ultrasound Obstet Gynecol 2011; 38: 134–139

First trimester maternal serum placental growth factor in trisomy 21 pregnancies*..............51 Cowans NJ, Stamatopoulou A, Spencer K. Prenat Diagn. 2010 May;30(5):449-53.

Maternal serum placental growth factor at 11-13 weeks in chromosomally abnormal pregnancies........................................................................................52 Zaragoza E, Akolekar R, Poon LC, Pepes S, Nicolaides KH. Ultrasound Obstet Gynecol. 2009 Apr;33(4):382-6.

Circulating angiogenic proteins in trisomy 13.............................................................................53 Bdolah Y, Palomaki GE, Yaron Y, Bdolah-Abram T, Goldman M, Levine RJ, Sachs BP, Haddow JE, Karumanchi SA. Am J Obstet Gynecol. 2006 Jan;194(1):239-45.

First trimester maternal serum placenta growth factor (PIGF) concentrations in pregnancies with fetal trisomy 21 or trisomy 18....................................................................54 Spencer K, Liao AW, Ong CY, Geerts L, Nicolaides KH. Prenat Diagn. 2001 Sep;21(9):718-22.

6

*DELFIA Chemistry used in PlGF assay

Contents Fetal Death An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study......................................................... 55-56 Romero R, Chaiworapongsa T, Erez O, Tarca AL, Gervasi MT, Kusanovic JP, Mittal P, Ogge G, Vaisbuch E, Mazaki-Tovi S, Dong Z, Kim SK, Yeo L, Hassan SS. J Matern Fetal Neonatal Med. 2010 May 12.

Macrosomia Prediction of macrosomia at birth in type-1 and 2 diabetic pregnancies with biomarkers of early placentation*...............................................................................................57 S Kuc, EJ Wortelboer, MPH Koster, HW de Valk, PCJI Schielen, GHA Visserb J Matern Fetal Neonatal Med. 2010 May 12.

*DELFIA Chemistry used in PlGF assay

7

Pre-eclampsia and SGA Combined Screening for Preeclampsia and Small for Gestational Age at 11–13 Weeks

DELFIA Chemistry used in PlGF assay

Poon L.C.Y., Syngelaki A., Akolekar R., Lai J., Nicolaides K.H. Vol. 33, No. 1, 2013 Issue release date: January 2013 Fetal Diagn Ther 2013;33:16–27

OBJECTIVE: To combine a specific algorithm for small for gestational age (SGA) without preeclampsia (PE) and another algorithm for PE in the prediction of SGA and PE. METHODS: This was a screening study of singleton pregnancies at 11–13 weeks including 1,426 (2.3%) that subsequently developed PE, 3,168 (5.1%) that delivered SGA neonates and 57,458 that were unaffected by PE and SGA. We developed a prediction algorithm for SGA requiring delivery before 37 weeks’ gestation (preterm-SGA) from maternal characteristics, uterine artery pulsatility index, mean arterial pressure, serum pregnancy-associated plasma protein-A and placental growth factor multiple of the median values. We then examined the performance of this algorithm individually and in combination with a previously reported algorithm for early-PE in the prediction of SGA and PE. RESULTS: When screen positivity was defined by risk cutoff of 1:200 using the algorithm for early-PE and the risk cutoff of 1:150 using the algorithm for preterm-SGA, the false positive rate was 10.9% and the detection rates of early-PE, late-PE, preterm-SGA and term-SGA were 95.3, 45.6, 55.5 and 44.3%, respectively.

8

Pre-eclampsia and SGA Maternal Characteristics, Mean Arterial Pressure and Serum Markers in Early Prediction of Preeclampsia

DELFIA Chemistry used in PlGF assay

Sylwia Kuc, Maria P. H. Koster, Arie Franx, Peter C. J. I. Schielen, Gerard H. A. Visser PLOS ONE, 2013; 8(5): e63546

OBJECTIVE: In a previous study, we have described the predictive value of first-trimester PregnancyAssociated Plasma Protein-A (PAPP-A), free b-subunit of human Chorionic Gonadotropin (fb-hCG), Placental Growth Factor (PlGF) and A Disintegrin And Metalloprotease 12 (ADAM12) for early onset preeclampsia (EO-PE; delivery, 34 weeks). The objective of the current study was to obtain the predictive value of these serum makers combined with maternal characteristics and first-trimester maternal mean arterial blood pressure (MAP) in a large series of patients, for both EO-PE and late onset PE (LO-PE; delivery, 34 weeks). METHODS: This was a nested case-control study, using stored first-trimester maternal serum from women who developed EO-PE (n = 68) or LO-PE (n = 99), and 500 uncomplicated singleton pregnancies. Maternal characteristics, MAP, and pregnancy outcome were collected for each individual woman and used to calculate prior risks for PE in a multiple logistic regression model. Models containing prior PE risks, serum markers, and MAP were developed for the prediction of EO-PE and LO-PE. The model-predicted detection rates (DR) for fixed 10% false-positive rates were calculated for EO-PE and LO-PE with or without the presence of a small-for-gestational age infant (SGA, birth weight,10th centile). RESULTS: The best prediction model included maternal characteristics, MAP, PAPP-A, ADAM12, and PlGF, with DR of 72% for EO-PE and 49% for LO-PE. Prediction for PE with concomitant SGA was better than for PE alone (92% for EO-PE and 57% for LO-PE). CONCLUSION: First-trimester MAP, PAPP-A, ADAM12, and PlGF combined with maternal characteristics and MAP are promising markers in the risk assessment of PE, especially for EO-PE complicated by SGA.

9

Pre-eclampsia and SGA Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy M. PARRA-CORDERO, R. RODRIGO†, P. BARJA, C. BOSCO†, G. RENCORET, A. SEPÚ LVEDA-MARTINEZ and S. QUEZADA Ultrasound Obstet Gynecol 2013; 41: 538–544 Objective: To develop a predictive model for preeclampsia using clinical, biochemical and ultrasound markers during the first trimester of pregnancy. METHODS: This was a nested case–control study within a pre-eclampsia screening project that involved 5367 asymptomatic pregnant women undergoing routine transvaginal uterine artery (UtA) Doppler at 11+0 to 13+6weeks. Following exclusions, there were 70 pregnant women who later developed pre-eclampsia and 289 control patients enrolled during the first trimester who had serum or plasma samples taken at enrolment available for the purposes of this study. Of these, 17 pregnancies were diagnosed with early-onset (delivery

Suggest Documents